MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
3.160
-0.100
-3.07%
After Hours: 3.109 -0.051 -1.60% 18:56 07/13 EDT
OPEN
3.190
PREV CLOSE
3.260
HIGH
3.192
LOW
3.040
VOLUME
2.07M
TURNOVER
--
52 WEEK HIGH
4.537
52 WEEK LOW
1.660
MARKET CAP
484.94M
P/E (TTM)
-2.5851
1D
5D
1M
3M
1Y
5Y
1D
Genflow appoints Gad Berdugo as independent non-executive chairman
PUBT · 17h ago
Weekly Report: what happened at EDIT last week (0629-0703)?
Weekly Report · 07/06 09:08
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday
Benzinga · 07/02 14:24
Weekly Report: what happened at EDIT last week (0622-0626)?
Weekly Report · 06/29 09:08
Weekly Report: what happened at EDIT last week (0615-0619)?
Weekly Report · 06/22 09:09
Editas Medicine Shareholders Back Board, Pay and Auditor
TipRanks · 06/18 21:50
Editas Medicine shareholders elect Connaughton, Levy as Class I directors at annual meeting
PUBT · 06/18 20:29
Weekly Report: what happened at EDIT last week (0608-0612)?
Weekly Report · 06/15 09:09
More
About EDIT
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.